Enhanced workflow, exceptional images
ASPIRE Cristalle, Fujifilm’s newest digital mammography system, combines state-of-the-art, Hexagonal Close Pattern (HCP) image capture technology and intelligent image processing, optimizing contrast and dose based on breast density. The result is exceptional imaging, optimized contrast, low dose and fast acquisition time.iCAD's mammography Computer Aided Detection (CAD) solution is now available on Fujifilm’s ASPIRE Cristalle full field digital mammography system.
Forward-thinking technology, Fujifilm innovation.
*compared to ASPIRE HD and ASPIRE HD plus
Radiologists using ASPIRE Cristalle with DBT will realize valuable, enhanced clinical efficacy compared to using full field digital mammography (FFDM) alone.
Fujifilm's proprietary technology makes it possible to lower dose while offering optimized contrast, even in dense breasts and implants.
The unique Comfort Paddle allows pressure to be more evenly and gently distributed across the breast compared to conventional, flexible paddles.
ASPIRE Cristalle, Fujifilm’s third-generation full-field digital mammography (FFDM) system, now delivers optimum image quality at a very low patient dose. A new white paper, Technology Advances in Mammography: Dose Reduction and Image Quality, highlights the recent advances in FFDM technology employed in the ASPIRE Cristalle system.
Download the white paper to learn how:
Download the white paper here.
Hexagonal Close Pattern (HCP) Direct Conversion Technology
Fujifilm works with the following partners to provide additional features for ASPIRE Cristalle, ASPIRE HD Plus and ASPIRE HD.
iCAD is an industry-leading provider of Computer-Aided Detection (CAD) technologies, advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD's Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of Intraoperative Radiation Therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and gynecological cancers.
For more information, call (877) iCADnow, or visit www.icadmed.com.
Volpara Solutions builds innovative, quantitative breast imaging solutions tools built on the Volpara algorithm which enables the generation of volumetric measurements of density, patient specific dose, breast compression and other factors that provide actionable intelligence designed to help maintain accuracy and consistent quality in breast screening.
To date, more than 2 million women have had their volumetric breast density analyzed using VolparaDensity. Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is used by radiologists to objectively assess density from both digital mammography and tomosynthesis images and help evaluate who might benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity is a reliable tool which automatically generates an objective, automatic measurement of volumetric breast density and a FDA cleared BI-RADS breast density category.
VolparaAnalytics assists in quality assurance by monitoring critical elements of the breast imaging process and generating key metrics to help understand the performance of technologists, readers, and mammography and tomosynthesis machines.
VolparaDose improves the accuracy of mammography dose reporting by using a standard mean glandular dose (MGD) algorithm along with patient-specific volumetric breast density to give a better estimate of the dose absorbed by the specific breast.
For more information, visit www.volparasolutions.com.